- Home
- CRDL vs AGEN Comparison
CRDL vs AGEN Comparison
Compare CRDL & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- AGEN
- Stock Information
- Founded
- CRDL 2017
- AGEN 1994
- Country
- CRDL Canada
- AGEN United States
- Employees
- CRDL N/A
- AGEN 316
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRDL Health Care
- AGEN Health Care
- Exchange
- CRDL Nasdaq
- AGEN Nasdaq
- Market Cap
- CRDL 102.0M
- AGEN 38.1M
- IPO Year
- CRDL N/A
- AGEN 2000
- Fundamental
- Price
- CRDL $0.93
- AGEN $1.61
- Analyst Decision
- CRDL Strong Buy
- AGEN Buy
- Analyst Count
- CRDL 3
- AGEN 4
- Target Price
- CRDL $9.00
- AGEN $8.00
- AVG Volume (30 Days)
- CRDL 241.3K
- AGEN 484.8K
- Earning Date
- CRDL 05-13-2025
- AGEN 03-11-2025
- Dividend Yield
- CRDL N/A
- AGEN N/A
- EPS Growth
- CRDL N/A
- AGEN N/A
- EPS
- CRDL N/A
- AGEN N/A
- Revenue
- CRDL N/A
- AGEN $103,463,000.00
- Revenue This Year
- CRDL N/A
- AGEN $32.21
- Revenue Next Year
- CRDL N/A
- AGEN N/A
- P/E Ratio
- CRDL N/A
- AGEN N/A
- Revenue Growth
- CRDL N/A
- AGEN N/A
- 52 Week Low
- CRDL $0.88
- AGEN $1.44
- 52 Week High
- CRDL $3.12
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- CRDL 34.45
- AGEN 21.45
- Support Level
- CRDL $0.88
- AGEN $1.44
- Resistance Level
- CRDL $1.18
- AGEN $1.77
- Average True Range (ATR)
- CRDL 0.08
- AGEN 0.13
- MACD
- CRDL -0.01
- AGEN 0.02
- Stochastic Oscillator
- CRDL 21.54
- AGEN 8.00
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).